GlassScriptPhysician profile
Mcgregor N Lott
NPI 1326263310
$4,349.78
in general payments reported to CMS, 2019-2025
26 companies · $996 in 2025
The $996 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $178 · 2021: $236 · 2022: $770 · 2023: $402 · 2024: $1,077 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,474.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,137.94 | 2019-2025 | Clareon, Luxor, Clareon Panoptix Pro |
| Harrow Eye, LLC | $452.61 | 2024-2025 | Iheezo, Triesence, Vevye |
| Alimera Sciences, INC. | $393.26 | 2019-2024 | Iluvien, Yutiq |
| Regeneron Healthcare Solutions, INC. | $382.51 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $204.17 | 2022-2025 | Syfovre |
| Bausch & Lomb Americas INC. | $192.36 | 2022-2025 | Xiidra, Envista Mx60 Iol, Miebo |
| Ani Pharmaceuticals, INC. | $173.31 | 2024-2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
| Notal Vision, INC. | $148.67 | 2024-2025 | Foresee Home |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $143.05 | 2019-2021 | |
| Astellas Pharma US INC | $138.19 | 2023-2025 | Izervay |
| Aerie Pharmaceuticals, INC. | $121.44 | 2019-2021 | |
| Rxsight INC | $107.14 | 2025 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Novartis Pharmaceuticals Corporation | $97.88 | 2019-2020 | |
| Coherus Oncology, INC. | $97.20 | 2022-2023 | |
| Sandoz INC. | $96.84 | 2024-2025 | Cimerli |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $91.57 | 2022-2024 | Acthar |
| Johnson & Johnson Surgical Vision, INC. | $85.70 | 2019-2023 | Tecnis Simplicity |
| Rayner Intraocular Lenses Limited | $78.29 | 2024-2025 | Rayone Emv, Rayone Aspheric, Rayone Spheric |
| Sun Pharmaceutical Industries INC. | $39.47 | 2025 | |
| Genentech USA, INC. | $37.16 | 2019-2022 | |
| Carl Zeiss Meditec USA, INC. | $34.74 | 2025 | |
| Eyepoint US, INC. | $26.07 | 2020 | |
| Shire North American Group INC | $20.26 | 2019 | |
| New World Medical,INC. | $17.36 | 2019 | |
| Amgen INC. | $16.68 | 2025 | Tepezza |
| Ocular Therapeutix, INC. | $15.91 | 2023 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mcgregor Lott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.